BLEPHAMIDE
LOE ApproachingNDAOPHTHALMICSUSPENSION
Approved
Sep 1961
Lifecycle
LOE Approaching
Competitive Pressure
30/100
Data completeness
3/8 — Basic
BLEPHAMIDE by AbbVie is clinical pharmacology corticosteroids suppress the inflammatory response to a variety of agents and they probably delay or slow healing. Approved for inflammatory conditions of the palpebral, bulbar conjunctiva, cornea and 7 more indications. First approved in 1961.
Drug data last refreshed 10h ago · AI intelligence enriched 2w ago
AI summarySynthesized from FDA + DailyMed + ClinicalTrials.gov data
BLEPHAMIDE is a fixed-dose combination ophthalmic suspension containing a corticosteroid and sulfacetamide sodium antibiotic for treating inflammatory eye conditions. It suppresses inflammatory response while providing bacteriostatic coverage against susceptible gram-positive and gram-negative organisms. The corticosteroid component inhibits edema, fibrin deposition, and leukocyte migration, while sulfacetamide restricts bacterial folic acid synthesis.
LOE Approaching
As an LOE-approaching product, the brand team is likely in optimization mode with focus on defending market share against generic and branded alternatives; expect smaller commercial footprint compared to growth-stage products.
Mechanism of Action
CLINICAL PHARMACOLOGY Corticosteroids suppress the inflammatory response to a variety of agents and they probably delay or slow healing. Since corticosteroids may inhibit the body's defense mechanism against infection, a concomitant antibacterial drug may be used when this inhibition is considered…
Indications (10)
Worked on BLEPHAMIDE at AbbVie? Share your interview experience or compensation data (+7 days Pro)
Data Sources
- Drug label: DailyMed / FDA
- Clinical trials: ClinicalTrials.gov
- Patent data: FDA Orange Book
- Spending data: CMS Medicare
The information on this page is for informational purposes only and should not be used as a substitute for professional medical advice. Drug information is sourced from FDA, DailyMed, and other government databases. Adverse event data from FAERS does not establish causation. Always consult a healthcare professional for medical decisions.